Evidence map›Paper›PMID 39526468›Full record

ArticleVeterinary and comparative oncology2025

Characterisation and Sensitivity of a Canine Mast Cell Tumour Line to Oncolytic Viruses.

Yeganeh Mehrani, Julia E Kakish, Christina Napoleoni, Jennifer Jane Thompson, Jason P Knapp, Jessica A Minott, Jacob G E Yates, Deirdre Stuart, Brenda L Coomber, Robert A Foster and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary and comparative oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yeganeh MehraniDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.ORCID https://orcid.org/0000-0002-3132-9795
Julia E KakishDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Christina NapoleoniDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Jennifer Jane ThompsonDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Jason P KnappDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Jessica A MinottDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Jacob G E YatesDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Deirdre StuartCompanion Animal Tumour Bank, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Brenda L CoomberDepartment of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.ORCID https://orcid.org/0000-0002-0776-5562
Robert A FosterDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Byram W BridleDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Khalil KarimiDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.

Funding

OVC Pet Trust #054725OVC Pet Trust #055676OVC Pet Trust #056009
6 · The paper itself

Abstract

Canine mast cell tumours (MCTs) are one of the most common skin cancers of dogs. Surgical removal is the primary treatment, but recurrence and metastasis can occur even with low-grade tumours. As a result, new treatment strategies are being sought. We tested the potential of several oncolytic viruses (OVs) to infect and kill a cell line isolated from a canine MCT. Employing a resazurin-based metabolic assay and flow cytometry technology, we used recombinant vesicular stomatitis virus (rVSV-Δm51), avian orthoavulavirus-1 (AOaV-1), and Orf viruses in our assessment. Our study aimed to evaluate the potential of oncolytic virotherapy in treating canine cancers. We found that MCT-1 cells showed different sensitivities to the OVs, with rVSV-Δm51 showing the most promising results in vitro. These findings suggest that further investigation into using OVs for treating canine MCTs is needed, although clinical efficacy is yet to be determined.

Indexed as

Dog DiseasesOncolytic VirotherapyOncolytic VirusesSkin NeoplasmsAnimalsCell Line, TumorDogscancercanine mast cell tumoursoncolytic virotherapyoncolytic viruses

Identifiers

PMID39526468
PMCPMC11830461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.